This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts Name Top Biotech Stocks for 2010: BioBuzz

NEW YORK ( TheStreet) -- 'Tis the season for sell-side analysts to issue their sector outlooks for the coming year.

The J.P. Morgan healthcare team released its 2010 forecast this morning, in advance of the firm's big healthcare conference next week in San Francisco. The firm's top biotech picks for 2010 are Celgene (CELG - Get Report), Incyte (INCY - Get Report), Ipsen and Actelion.

J.P. Morgan's Geoff Meacham's macro view of the biotech sector:

"In 2010, we are cautiously optimistic on the group with a bias toward small and mid caps and selectivity among the large caps. The worst may be behind us regarding healthcare reform fears, and further multiple compression seems unlikely, but overall sentiment remains negative toward the group, which could create an attractive entry point. We think 2010 will be a year when performance is event-driven, not earnings-driven, given maturation of the biotech sector and the emphasis on sustainability of growth."

Meacham on small and mid-cap biotech in 2010:

"Small and mid caps should continue to lead innovation in the sector, which could spark M&A activity and a favorable deal environment. In addition, a rebirth of the biotech IPO in 2010 could be a big positive for the group by disproving the notion that pipelines within the industry are thin and by expanding the investable universe. Valuation-wise, small and mid caps are not cheap (4.4X EV/Rev, up from 4X in early 2009) but should broadly benefit from high scarcity value, upside growth prospects and good access to capital."

Meacham on 2010 M&A activity:

"Pharma companies at the 2009 J.P. Morgan Healthcare Conference cited a willingness to do 'more deals and bigger deals,' leading us and the Street to infer that there would be increased biotech M&A last year. 'More deals' didn't really materialize in 2009, with four announced deals with public biotech companies...

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
ACOR $31.44 -5.07%
AMGN $162.38 -3.29%
CELG $114.72 -3.37%
INCY $101.38 -5.55%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs